Saturday, March 24, 2018

Tuesday, 19 September 2017 Divani Caravel Hotel



Health Daily is a daily, electronic newsletter, providing its subscribers with reliable and comprehensive information on health and pharma industry in Greece. It includes news for political and financial decisions and evolutions of health, such as healthcare reforms, strategic alliances between pharmaceutical companies, international news etc. In this context, Health Daily organizes a variety of specific conferences for Healthcare Sector such as “The Future of Healthcare in Greece” and the «Patients in Power” Conference.


GENESIS Pharma was among the first pharmaceutical companies in Europe specialized in biopharmaceutical products and is currently the largest among Greek companies specializing in branded innovative medicines. The company has created a strong product portfolio that includes high-tech pharmaceutical products for severe and rare diseases, through long standing strategic alliances for the broader region of Southeast Europe with some of the leading multinational pharmaceutical companies committed to cutting edge R&D.
GENESIS Pharma maintains a wide product portfolio for rare hematological malignancies and threatening cancers, such as multiple myeloma, leukemia, metastatic pancreatic cancer and metastatic breast cancer, while it is considered as one of the most specialized companies in multiple sclerosis in Greece. Its portfolio also includes products in the therapeutic areas of dermatology, rheumatology and nephrology.

Novartis Group has a leading position in the Greek Pharmaceuticals Sector. It has been active in Greece for more than 20 years, with a diversified portfolio including innovative medicines (Novartis), holistic eye care (Alcon) and generics (Sandoz). Novartis' portfolio includes more than 50 innovative products, many of which are leaders in therapeutic areas such as cardiometabolic diseases, the Immunology and Dermatology, the Neurosciences, the respiratory disease, Ophthalmology, Oncology and Haematology. In the period 2013-2015 the company invested 138.2 mio Euros in Greek society, through R&D, tax payments, payroll, suppliers, donations and sponsorships, while our investments to approximately 200 clinical trials is more than 18 mio. Euros.


Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at

Who is QuintilesIMS?
In October 2016, the IMS Health, a leading company in providing information and technology solutions for the healthcare industry, merged with Quintiles, the largest provider of clinical trials and drug development services, creating QuintilesIMS, a world leader in the provision of information and integrated health services through leading technology solutions with global reach and a full range of integrated clinical and commercial services.

At Janssen, the Pharmaceutical Companies of Johnson & Johnson, we are actively developing treatments for our patients in five important therapeutic areas of healthcare (Oncology, Neuroscience, Immunology, Infectious diseases & vaccines, Cardiovascular & Metabolic diseases). We are focused on operating in transparency and on building trust. We work for change that will improve access to medicines: the best available treatment at an affordable price. We are looking at a future where patients and their families have a new sense of hope. Hope for a cure.
For more information, please visit us at


Στην MSD, πάντοτε ανακαλύπταμε και θα συνεχίσουμε να εφευρίσκουμε έχοντας έναν και μόνο απώτερο σκοπό: περισσότερη και καλύτερη ζωή. Εδώ και πάνω από έναν αιώνα, οι άνθρωποί μας εργάζονται ακατάπαυστα για να εφευρίσκουν λύσεις για τις περισσότερες από τις πιο σοβαρές ασθένειες που απειλούν την ανθρωπότητα παγκοσμίως. Πρωτοπόρες θεραπείες για τον καρκίνο, τις καρδιοπάθειες, το HIV, τον διαβήτη και τη φυματίωση είναι μερικές μόνο από τις εφευρέσεις μας που έφεραν ελπίδα και βελτίωσαν τη ζωή των συνανθρώπων μας. Σήμερα, συνεχίζουμε με την ίδια προσήλωση και βρισκόμαστε στην πρωτοπορία της έρευνας για να μετατρέψουμε την επιστημονική γνώση σε θεραπείες για την πρόληψη και αντιμετώπιση παγκόσμιων υγειονομικών προβλημάτων, όπως ο καρκίνος, οι καρδιομεταβολικές παθήσεις, η νόσος του Αλτσχάιμερ και οι μεταδοτικές ασθένειες όπως ο HIV και ο ιός Έμπολα. Θέλουμε οι εφευρέσεις μας να φτάνουν σε κάθε γωνιά του πλανήτη. Στην Ελλάδα, θέλουμε να προσφέρουμε νέες θεραπείες για διάφορες μορφές νεοπλασιών, το διαβήτη, την αθηροσκλήρωση, την ηπατίτιδα C, καθώς και θεραπευτικές λύσεις στον τομέα των αντιβιοτικών και των εμβολίων. Διευρύνουμε τα όρια της επιστήμης με την ελπίδα ότι τα φάρμακα και τα εμβόλια που εφευρίσκουμε θα βελτιώσουν την υγεία όχι μόνο της σημερινής αλλά και των επόμενων γενεών.


Conferience is an interactive web-app facilitating direct interactive possibilities among speakers and audiences for events such as: lectures, presentations, conferences, polling, training courses, seminars, focus groups, research & (executive) meetings.

Become a sponsor

For more details about the levels of sponsorship and the associated benefits please contact with:

Chrisoula Kordouli, tel.: +30 210 661 77 77 (ext. 266), fax: +30 210 661 77 78, e-mail:

© 2018 Boussias Communications, all rights reserved., T:210 6617777, F:210 6617778

Designed by Boussias
New Media Team